• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AJMC® in the Press, June 8, 2018

Article

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

The National Pharmaceutical Council’s Monday CER Daily Newsfeed included The American Journal of Managed Care® (AJMC®)'s coverage of the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 1-5 in Chicago, Illinois. The article, “Clinical Trials: Sharing the Road With Real-World Evidence,” covered a panel discussion on collecting and using real-world data in combination with clinical trial results to inform evidence-based care.

Thursday’s OBR Oncology daily newsfeed included ASCO coverage from AJMC®'s The Center for Biosimilars®. The article, “Researchers Report Findings on Three Biosimilar Trastuzumab Products,” covered study results that found 1-year safety and survival data of Samsung Bioepis’ SB3 support biosimilarity, central evaluations from LILAC further the clinical equivalence of Amgen’s ABP 980 and reference trastuzumab, and Biocad’s Herticad reduced the cost of trastuzumab therapy by 75%.

Related Videos
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.